Quince Therapeutics, Inc. — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Quince Therapeutics filed an 8-K on 2026-08-27 reporting Item 5.02 (departure of directors/officers and compensatory arrangements). The filing header indicates a personnel/compensation matter occurred on 2026-08-23, but the specific details—name of departed officer, role, severance terms, equity treatment, replacement appointment, or exact compensation amounts—are not provided in the metadata extract. The full document text would be required to identify the counterparty and concrete financial terms.
Why this rating
Item 5.02 is routine disclosure; without specific termination/compensation detail, cannot assess materiality. At $64M market cap, executive departure could matter if senior, but standard process disclosure alone is low-impact.
Extracted items
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.